OncoFirm Diagnostics Announces Launch and Opens First Round Funding Opportunities Up to $10 Million
FOR IMMEDIATE RELEASE
Contact: Jonathan Adam Barash
Email: press@oncofirmdiagnostics.com
Phone: 516-900-2606
Website: www.oncofirmdiagnostics.com
OncoFirm Diagnostics Corp. Announces Launch and Opens First Round Funding Opportunities Up to $10 Million
Revolutionizing Early Cancer Detection Through Rapid, Antigen-Based Screening Technology
Port Washington, New York — April 7 — OncoFirm Diagnostics Corp., a cutting-edge medical diagnostics company, today announced its official launch and the opening of its first round of investment funding, with opportunities of up to $10 million available to qualified investors. The funding will support regulatory clearance, commercial-scale manufacturing, clinical validation, and international market expansion for the company’s flagship product line of rapid cancer screening tests.
Using advanced lateral flow assay (LFA) technology and targeting tumor-specific Thomsen-Friedenreich (TF) and Gal-GalNAc antigens, OncoFirm’s platform enables non-invasive, cost-effective, and highly accurate cancer diagnostics at the point of care—in under 15 minutes.
“Our goal is to democratize early cancer detection,” said Jonathan Adam Barash, Founder and CEO of OncoFirm Diagnostics. “With our unique antigen-driven technology, we’re giving healthcare providers, clinics, and hospitals the tools to catch cancer earlier, more affordably, and in more places—including those with limited access to laboratory infrastructure.”
The company’s initial test pipeline rapid cancer tests include:
- OncoScreen-R – Colorectal & pancreatic cancer test
- OncoScreen-B – Breast & ovarian cancer test
- OncoScreen-L – Lung cancer panel
- OncoMultiDx – Multiplex test detecting multiple cancers from a single sample
- OncoScreen-PSA – Prostate
- OncoScreen-AFP – Liver
- OncoScreen-CEA – Gastrointestinal cancers
OncoFirm Diagnostics is pre launching CE-marking its first products for distribution in Europe, Latin America, and Asia, with FDA submission underway for U.S. market access. The funding will also support recruitment in R&D, regulatory affairs, and commercial operations.
Investment Highlights:
- Target raise: $10 million (Seed + Series A)
- Use of funds: Finish Product Development, CE/FDA regulatory clearance, clinical trials, scale-up, hiring
- Global cancer diagnostics market projected to exceed $280 billion by 2030
- Strategic entry into underserved cancer screening markets and decentralized healthcare environments
“We are positioned at the intersection of global need and scientific innovation,” said Jonathan Adam Barash. “This funding round is an opportunity to partner with us at a transformative moment—not only for our company but for the future of early cancer detection.”
About OncoFirm Diagnostics
OncoFirm Diagnostics develops rapid diagnostic tests for cancer using proprietary antigen targeting and next-generation lateral flow technology. Designed for medical institutions and point-of-care settings, OncoFirm’s solutions are reshaping early detection and expanding global access to life-saving screening tools.
For investment inquiries or to request a pitch deck, please contact:
Jonathan Adam Barash
Investor Relations, OncoFirm Diagnostics
investor@oncofirmdiagnostics.com | 516-900-2606
www.oncofirmdiagnostics.com
